Halozyme Therapeutics Inc (NASDAQ:HALO) — Market Cap & Net Worth
Market Cap & Net Worth: Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics Inc (NASDAQ:HALO) has a market capitalization of $8.70 Billion ($8.70 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2491 globally and #917 in its home market, demonstrating a -3.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Halozyme Therapeutics Inc's stock price $106.25 by its total outstanding shares 117597000 (117.60 Million). Also see balance sheet size of Halozyme Therapeutics Inc for a full breakdown of the balance sheet.
Halozyme Therapeutics Inc Market Cap History: 2015 to 2026
Halozyme Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $2.04 Billion to $12.49 Billion (20.02% CAGR). Also see HALO operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Halozyme Therapeutics Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 0.82% | #22 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.75% | #15 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.33% | #58 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #290 of 3165 |
|
S&P Midcap 400
MID
|
$3.41 Trillion | 0.29% | #151 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.46% | #40 of 263 |
Weight: Halozyme Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Halozyme Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Halozyme Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Halozyme Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.54x
Halozyme Therapeutics Inc's market cap is 5.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.66x
Halozyme Therapeutics Inc's market cap is 12.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.04 Billion | $135.06 Million | -$32.23 Million | 15.09x | N/A |
| 2016 | $1.16 Billion | $146.69 Million | -$103.02 Million | 7.92x | N/A |
| 2017 | $2.38 Billion | $316.61 Million | $62.97 Million | 7.53x | 37.84x |
| 2018 | $1.72 Billion | $151.86 Million | -$80.33 Million | 11.33x | N/A |
| 2019 | $2.08 Billion | $195.99 Million | -$72.24 Million | 10.64x | N/A |
| 2020 | $5.02 Billion | $267.59 Million | $129.09 Million | 18.77x | 38.91x |
| 2021 | $4.73 Billion | $443.31 Million | $402.71 Million | 10.67x | 11.74x |
| 2022 | $6.69 Billion | $660.12 Million | $202.13 Million | 10.14x | 33.10x |
| 2023 | $4.35 Billion | $829.25 Million | $281.59 Million | 5.24x | 15.43x |
| 2024 | $5.62 Billion | $1.02 Billion | $444.09 Million | 5.54x | 12.66x |
Competitor Companies of HALO by Market Capitalization
Companies near Halozyme Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review how tangible is Halozyme Therapeutics Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Halozyme Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Halozyme Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Halozyme Therapeutics Inc's market cap moved from $2.04 Billion to $ 12.49 Billion, with a yearly change of 20.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.49 Billion | +57.88% |
| 2025 | $7.91 Billion | +40.77% |
| 2024 | $5.62 Billion | +29.36% |
| 2023 | $4.35 Billion | -35.04% |
| 2022 | $6.69 Billion | +41.51% |
| 2021 | $4.73 Billion | -5.85% |
| 2020 | $5.02 Billion | +140.89% |
| 2019 | $2.08 Billion | +21.19% |
| 2018 | $1.72 Billion | -27.79% |
| 2017 | $2.38 Billion | +105.06% |
| 2016 | $1.16 Billion | -42.99% |
| 2015 | $2.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Halozyme Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.70 Billion USD |
| MoneyControl | $8.70 Billion USD |
| MarketWatch | $8.70 Billion USD |
| marketcap.company | $8.70 Billion USD |
| Reuters | $8.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more